Neurocrine Biosciences shares are trading lower despite its Phase 2 study of NBI-1117568 in schizophrenia meeting its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences shares are trading lower even though its Phase 2 study of NBI-1117568 in schizophrenia met its primary endpoint.
August 28, 2024 | 11:52 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Neurocrine Biosciences' stock is trading lower despite achieving the primary endpoint in its Phase 2 study for NBI-1117568 in schizophrenia.
The stock price of Neurocrine Biosciences is declining despite the positive news of meeting the primary endpoint in a Phase 2 study. This suggests that investors may have had higher expectations or there may be other factors influencing the stock negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100